BACKGROUND: Liver metastases are relatively common in patients with metastatic medullary thyroid carcinoma (MTC), carrying a negative impact on disease prognosis. The options for selective therapy of liver metastases in MTC patients are limited to catheter-guided procedures such as trans-arterial chemoembolization (TACE). Data regarding the effectiveness and safety of this procedure in MTC are limited. AIM: To explore the clinical outcome, survival and safety profile of TACE for liver metastases in a group of MTC patients. METHODS: Retrospective case series of patients treated at a single tertiary University Medical Center from 2005 to 2015. RESULTS: Seven consecutive patients (mean age 64.5 ± 10.9 years, 5 females) with histologically confirmed MTC with liver metastases were included. Metastatic involvement of the liver was less than 50% of the liver volume in all patients. The median size of the largest liver lesion was 40 ± 6.9 mm. The patients underwent in total 20 sessions of TACE. Clinical improvement as well as tumor response (PR) were observed in all patients. The median time to tumor progression was 38 months (range 8-126). Three patients were still alive at the end of the follow-up period (a median overall survival rate of 57 ± 44 months). CONCLUSION: TACE in MTC patients with hepatic metastases is usually well tolerated and induces both clinical improvement and tumor response for prolonged periods of time in the majority of patients. This therapeutic option should always be considered, irrespective of the presence of extrahepatic metastasis.
BACKGROUND:Liver metastases are relatively common in patients with metastatic medullary thyroid carcinoma (MTC), carrying a negative impact on disease prognosis. The options for selective therapy of liver metastases in MTC patients are limited to catheter-guided procedures such as trans-arterial chemoembolization (TACE). Data regarding the effectiveness and safety of this procedure in MTC are limited. AIM: To explore the clinical outcome, survival and safety profile of TACE for liver metastases in a group of MTC patients. METHODS: Retrospective case series of patients treated at a single tertiary University Medical Center from 2005 to 2015. RESULTS: Seven consecutive patients (mean age 64.5 ± 10.9 years, 5 females) with histologically confirmed MTC with liver metastases were included. Metastatic involvement of the liver was less than 50% of the liver volume in all patients. The median size of the largest liver lesion was 40 ± 6.9 mm. The patients underwent in total 20 sessions of TACE. Clinical improvement as well as tumor response (PR) were observed in all patients. The median time to tumor progression was 38 months (range 8-126). Three patients were still alive at the end of the follow-up period (a median overall survival rate of 57 ± 44 months). CONCLUSION: TACE in MTC patients with hepatic metastases is usually well tolerated and induces both clinical improvement and tumor response for prolonged periods of time in the majority of patients. This therapeutic option should always be considered, irrespective of the presence of extrahepatic metastasis.
Authors: Daniel Puhr-Westerheide; Clemens C Cyran; Josef Sargsyan-Bergmann; Andrei Todica; Franz-Josef Gildehaus; Wolfgang G Kunz; Robert Stahl; Christine Spitzweg; Jens Ricke; Philipp M Kazmierczak Journal: Cancer Imaging Date: 2019-11-14 Impact factor: 3.909
Authors: Alice Nervo; Alberto Ragni; Francesca Retta; Marco Calandri; Carlo Gazzera; Marco Gallo; Alessandro Piovesan; Emanuela Arvat Journal: J Gastrointest Cancer Date: 2021-05-17